Funding Rounds
Asgard Therapeutics

Asgard Therapeutics Series A (2024, $30M)

Asgard Therapeutics

Developer of vivo direct cell reprogramming for cancer immunotherapy.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series A

Raised Amount: $30.00M

Investors